Drug intelligence / Profile preview

JMKX003142 + rifampicin

Development stage: Phase 1
Lead developer: Jemincare
Modality: Small Molecules
Administration: Oral, Injection

Overview

JMKX003142 + rifampicin is a combination of JMKX003142, a novel small molecule drug with CYP inhibitor activity, and rifampicin, an established antibiotic. JMKX003142 is being developed for conditions including autosomal dominant polycystic kidney disease (ADPKD), heart failure with volume overload, and edema. The combination with rifampicin is not specifically described in available information.

Targets

PXR (Pregnane X receptor)Cyp (Cyclophilin family)

Beyond the preview

Go deeper on JMKX003142 + rifampicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JMKX003142 + rifampicin.